Company Profile

Goldshield Group Limited (Goldshield) is a marketing-led British Pharmaceutical and Consumer Health company. The company markets its products in more than 50 countries across the globe with primary focus in UK and EU markets. Goldshield has operational base in the UK, USA and India.

Goldshield sells prescription pharmaceuticals, non-prescription medicines, vitamins, minerals and supplements and a wide range of other healthcare products.

Goldshield was delisted in December 2009 a result of a Management Buy Out by Midas Bidco Limited. Prior to this the group was listed on the London Stock Exchange since 1998. Goldshield has grown to its present size with equity funding of only £1.8 million up to 31 March 1998 having commenced trading in 1991.

Goldshield is accredited ‘Investor in People’ and lays significant emphasis on continuous training and development of its employees.

Goldshield’s business is broadly classified into two product groups - Pharmaceuticals and Consumer Health.

..................................................................................................................................................................................................................... TOP

Pharmaceuticals

Pharmaceuticals markets products for the treatment or prevention of chronic or recurrent illnesses. Goldshield currently markets products which address indications in focus therapeutic areas of Pain & Anaesthesia, Cardiovascular, and Joint & Musculosceletal. The Company distributes its products through retail pharmacies, hospitals and international country distributor network.

This product group serves with a diversified range of therapeutics through broad categories - Specialty Brands needing strong marketing support and lower maintenance costs, Mature Brands requiring limited selling support and Value Generics requiringhigh selling and operational support

Manufacturing and product development is outsourced to reliable established players.

The growth of pharmaceuticals has resulted principally from the Company’s policy of acquiring the UK and Irish rights to marketed products with growth potential with the intention that these would finance further acquisitions and product development programmes. The acquired products have been supplemented, where appropriate, by product line extensions which have led to cost effective and low risk organic growth.

..................................................................................................................................................................................................................... TOP

Consumer Health

Consumer Health covers four of the major healthcare categories: Weight Management, Joints and Mobility, Female Wellbeing and Vanity and Male Wellbeing and Vanity. Its product portfolio consists of vitamins, minerals and supplements, analgesics, skin care, herbal medicines, cough and cold remedies and slimming aids.

Direct grasp of the consumer needs and responding by reaching out with accurate products, have been the operational crux of the consumer health arm. The marketing constitution thus aptly comprises Retail as well as Direct selling routes.

Almost all growth in Consumer Health has been organic. This is largely due to   investment in successful customer service via personal medical support centre and continuous education programs.

Manufacturing and product development is outsourced to reliable established players across Europe, USA and Asia.

The Company believes that the product portfolio growth has been and will continue to be achieved through the Group's focus on its customers, its marketing-led approach and its ability to offer a wide range of products with a common brand identity.

..................................................................................................................................................................................................................... TOP

Group Vision

“We will be recognised as a successful growing, marketing led ethical provider of quality innovative pharmaceutical products, medical devices, consumer health and lifestyle brands to targeted international and niche markets.

We will be passionate about building the Goldshield brand. Our people will be our strength and will be empowered to meet our customers’ needs and expectations”

..................................................................................................................................................................................................................... TOP

The Future

Goldshield aims to continue to grow through product acquisition and strategic alliances. The next few years will see a stream of new Goldshield products coming onto the market.

Demand for quality healthcare products has grown dramatically over the past few years and this demand will continue to accelerate in the future. In order to meet this demand, the Company is constantly developing new products and creating new distribution channels, which include retail outlets and the Internet.

The Company believes that growth has been and will continue to be achieved through the Group's marketing-led approach and its ability to offer a wide range of products. Therefore, the future growth will through the pursuit of strategies relating to:

• In-Licensing of niche Specialty Brands and Strategic Brands
• Brand Leverage (reclassification)
• Product Development (line extensions)
• Distribution agreements with multinationals to manage their non-core product portfolio

..................................................................................................................................................................................................................... TOP

History

The Group was founded and commenced trading in 1991 with a range of pharmaceutical and healthcare products.

The first pharmaceutical product was acquired from Glaxo in 1992 and there have been subsequent product acquisitions from SmithKline Beecham, Medeva, Warner Lambert, Wyeth and American Home Products.

Between 1991 and 1993, the Group raised equity finance of £1.0 million from individual investors, many of whom are doctors, pharmacists, or from within the pharmaceutical industry. The Group became profitable in the year ended 31 March 1993.

During 1993, the Group started to sell Healthcare products direct to consumers through mail order, and started the development of its own Pharmaceutical products in 1995. It received its first UK marketing authorisation for a pharmaceutical product licensed to and developed by the Group in 1996.

• In 1997, the Healthcare Division's distribution and call-centre was opened.

• In June 1998, the Group was floated on the London Stock exchange.

• In December 2009 the Group was delisted as a result of the Management Buy out by Midas Bidco Limited.

..................................................................................................................................................................................................................... TOP